Abnormal movements and tardive dyskinesia in smokers and nonsmokers with schizophrenia genotyped for cytochrome P450 2D6

Pharmacotherapy

Volumn 22, Issue 11, 2002, Pages 1416-1419

  Ellingrod, Vicki L ^a,b   Schultz, Susan K ^b   Arndt, Stephan ^b  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORPROMAZINE; CYTOCHROME P450 2D6; CYTOCHROME P450 ISOENZYME; HALOPERIDOL; NEUROLEPTIC AGENT; NEUROTOXIN; PYRIDINIUM DERIVATIVE;

ADULT; ARTICLE; CIGARETTE SMOKING; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EXPOSURE; DRUG METABOLISM; ENZYME ACTIVITY; FEMALE; GENOTYPE; HUMAN; LINEAR REGRESSION ANALYSIS; MALE; MENTAL DISEASE; MOTOR DYSFUNCTION; RATING SCALE; SCHIZOPHRENIA; SCORING SYSTEM; SEX; TARDIVE DYSKINESIA;

EID: 0036844154     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.22.16.1416.33700     Document Type: Article

References (23)

1. Maghoub A, Idle JR, Dring LG, Lancaster R, Smith RL. Polymorphic hydroxylation of debrisoquine in man. Lancet 1997;2:584-6.
2. Vinks A, Inaba T, Otton SV, Kalow W. Spartein metabolism in Canadian Caucasians. Clin Pharmacol Ther 1982;31:23-9.
3. Nakamura K, Goto F, Ray WA, et al. Interethnic differences in genetic polymorphism of debrisoquine and mephenytoin hydroxylation between Japanese and Caucasian population. Clin Pharmacol Ther 1985;38:402-8.
4. Sachse C, Brockmoller J, Baue S, Roots I. Cytochrome P450 2D6 variants in a Caucasian population: Allele frequencies and phenotypic consequences. Am J Hum Genet 1997;60:284-95.
5. Zevin S, Benowitz N. Drug interactions with tobacco smoking: An update. Clin Pharmacokinet 1999;36:425-38.
6. Casey DE, Hansen TE. Spontaneous dyskinesia. In: Jeste DV, Wyatt RJ, eds. Neuropsychiatric Movement Disorders. Washington, DC: American Psychiatric Press, 1984:68-95.
7. Kapitany T, Meszaros K, Lenzinger E, et al. Genetic polymorphism for drug metabolism (CYP2D6) and tardive dyskinesia in schizophrenia. Schizophr Res 1998;32:101-6.
8. Ohmori O, Suzuki T, Kojima H, et al. Tardive dyskinesia and debrisoquine 4-hydroxylase (CYP2D6) genotype in Japanese schizophrenics. Schizophr Res 1998;32:107-13.
9. Ellingrod VL, Schultz SK, Arndt S. Association between cytochrome P4502D6 (CYP2D6) genotype, antipsychotic exposure, and Abnormal Involuntary Movement Scale (AIMS) score. Psychiatric Genet 2000;10:9-11.
10. Kirch DG, Alho AM, Wyatt RJ. Hypothesis: A nicotine-dopamine interaction linking smoking with Parkinson's disease and tardive dyskinesia. Cell Mol Neurobiol 1988;8:285-90.
11. Yassa R, Lal S, Korpassy A, Ally J. Nicotine exposure and tardive dyskinesia. Biol Psychiatry 1987;22:67-72.
12. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th Ed. Washington, DC: American Psychiatric Association, 1994.
13. Flaum MA, Andreasen NC, Arndt S. The Iowa prospective longitudinal study of recent-onset psychoses. Schizophr Bull 1992;18:481-90.
14. Heim M, Meyer UA. Genotyping of poor metabolizer of debrisoquine by allele-specific PCR amplification. Lancet 1990;336:529-32.
15. Heim MH, Meyer UA. Genetic polymorphism of debrisoquine oxidation: Restriction fragment analysis and allele-specific amplification of mutant alleles of CYP2D6. Methods Enzymol 1991;206:173-83.
16. Guy W. Abnormal involuntary movement scale. In: ECDEU Assessment Manual for Psychopharmacology. Washington, DC: U.S. Public Health Service, 1976:534-7.
17. Schooler NR, Kane JM. Research diagnoses for tardive dyskinesia. Arch Gen Psychiatry l982;39:486-7.
18. Pan L, Belpaire KM. In vitro study on the involvement of CYP1A2, CYP2D6, and CYP3A4 in the metabolism of haloperidol and reduced haloperidol. Eur J Clin Pharmacol 1999;55:599-604.
19. Miller DD, Kelly MW, Perry PJ, Coryell WH. The influence of cigarette smoking on haloperidol pharmacokinetics. Biol Psychiatry 1990;28:529-31.
20. Pan L, Vander Stichele R, Rosseel MT, Berlo JA, De Schepper N, Belpaire FM. Effects of smoking, CYP2D6 genotype, and concomitant drug intake on the steady state plasma concentrations of haloperidol and reduced haloperidol in schizophrenic inpatients. Ther Drug Monit 1999;21:489-97.
21. Igarashi K, Kasuya F, Fukui M, Usuki E, Castagnoli N. Studies on the metabolism of haloperidol (HP): The role of CYP3A in the production of the neurotoxic pyridinium metabolite HPP+ found in rat brain following IP administration of HP. Life Sci 1995;57:2439-46.
22. Usuki E, Pearce R, Parkinson A, Castagnoli N. Studies on the conversion of haloperidol and its tetrahydropyridine dehydration product to potentially neurotoxic pyridinium metabolites by human liver microsomes. Chem Res Toxicol 1996;9:800-6.
23. Wright AM, Bempong J, Kirby ML, Barlow RL, Bloomquist JR. Effects of haloperidol metabolites on neurotransmitter uptake and release: Possible role in neurotoxicity and tardive dyskinesia. Brain Res 1998;788:215-22.